Diagram illustrating the 2-year post-recurrence survival rates. Patients expressing NY-ESO-1 and those that did not had 2-year post-recurrence survival rates of 69.8% and 71.4%, respectively (P = 0.35, log-rank test). For NY-ESO-1 negative patients, there were 38 patients, 10 deaths, and the median survival time (after recurrence) has not been reached. For NY-ESO-1 positive patients, there were 18 patients, 8 deaths, and the median survival time (after recurrence) was 2.8 years (95% CI = 1.4-4.2 years). The median follow-up time for metastatic cohort (post-recurrence) was 2.1 years (min=0.1 years, max=11.8 years).